US7574682024 - RDHL - A3D9SL (XNMS)
REDHILL B.S.AD 400/IL-,01 Hinterlegungsschein
9,22 EUR
Aktuelle Kurse von REDHILL B.S.AD 400/IL-,01
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
RDHL
|
USD
|
19.09.2024 22:44
|
10,30 USD
| 9,87 USD | 4,36 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | -8,70 % | -95,24 % | -95,59 % | -23,71 % | -50,70 % | -99,87 % |
Firmenprofil zu REDHILL B.S.AD 400/IL-,01 Hinterlegungsschein
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Unternehmensdaten REDHILL B.S.AD 400/IL-,01 Hinterlegungsschein
Name REDHILL B.S.AD 400/IL-,01
Firma RedHill Biopharma Ltd.
Symbol RDHL
Website https://www.redhillbio.com
Heimatbörse
Frankfurt
WKN A3D9SL
ISIN US7574682024
Wertpapierart Hinterlegungsschein
Sektor Healthcare
Branche Drug Manufacturers - Specialty & Generic
CEO Mr. Dror Ben-Asher
Marktkapitalisierung 12 Mio
Land Israel
Währung EUR
Mitarbeiter 0,1 T
Adresse 21 Ha’arba’a Street, 6473921 Tel Aviv
IPO Datum 2013-01-07
Aktien-Splits
Datum | Split |
---|---|
22.08.2024 | 1:25 |
20.08.2024 | 1:25 |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | 2RH0.F |
NASDAQ | RDHL |
Weitere Aktien
Investoren die REDHILL B.S.AD 400/IL-,01 halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024